Skip to Content


Paperwork Reduction Act; Notice of Intent To Collect; Comment Request

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Office of National Drug Control Policy (ONDCP).


ONDCP provides opportunity for public comment concerning the collection of information gathered for the purpose of developing and tracking anti-drug advertising for the National Youth Anti-Drug Media Campaign.


This action proposes the renewal of three existing data collection instruments used in the production of ONDCP's National Youth Anti-Drug Media Campaign advertising and Media Campaign tracking.

End Preamble Start Supplemental Information


I. Purpose

The National Youth Anti-Drug Media Campaign is in the process of renewing three data collection instruments. These data collection instruments—pre-production qualitative (or “focus group”) testing of creative advertising concepts (OMB 3201-0011), pre-broadcast quantitative (or “copy”) testing of developed advertising (OMB 3201-0006) and a tracking study to measure advertising effectiveness (OMB 3201-0010)—are critical to the continuity and improvement of the Media Campaign and are key contributors to the downturn in drug abuse.

Type of Collections: OMB 3201-0011—Qualitative Research—Focus groups; OMB 3201-0006—Copytesting—15-minute mall intercept interviews; OMB 3201-0010—Tracking Study—15-minute mall intercept interviews.

Title of Collection: See above.

Frequency: OMB 3201-0011—Qualitative Research—Quarterly; OMB 3201-0006—Copytesting—Quarterly; OMB 3201-0010—Tracking Study—Weekly.

Affected Public: Teenagers and adult influencers of teenagers.

Estimated Burden: OMB 3201-0011—Qualitative Research—$11,600; OMB 3201-0006—Copytesting—$16,500; OMB 3201-0010—Tracking Study—$21,000.

II. Special Issues for Comment

ONDCP especially invites comments on: (a) Ways to enhance information quality, utility, and clarity of the collection instruments; and (b) ways to ease the burden on respondents, including the use of automated collection techniques or other forms of information technology.

Comments: Address comments within 60 days to Mark Krawczyk, Executive Office of the President, Office of National Drug Control Policy, Washington, DC 20503; by e-mail at; or, by fax at (202) 395-0858. For further information, contact Mr. Krawczyk at (202) 395-6720.

Start Signature

Signed in Washington, DC, on November 3, 2008.

Daniel R. Petersen,

Assistant General Counsel.

End Signature End Supplemental Information

[FR Doc. E8-26553 Filed 11-6-08; 8:45 am]